$--
(Market cap
$2 Mln
Recently Viewed
Clear AllMarket cap
$2 Mln
Revenue (TTM)
$9 Mln
P/E Ratio
--
P/B Ratio
1.2
Div. Yield
0 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-45 Mln
ROE
-4.2 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-0.7
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
28,682,300
CFO
$-379.65 Mln
EBITDA
$-483.59 Mln
Net Profit
$-616.01 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
VBI Vaccines Inc. New (Canada) (VBIV)
| -96.9 | -71.4 | -97.0 | -98.5 | -94.4 | -74.5 | -60.6 |
|
BSE Sensex*
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
VBI Vaccines Inc. New (Canada) (VBIV)
| -95.0 | -83.3 | -14.9 | 99.3 | -13.8 | -62.3 | 37.7 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers hepatitis B (HBV) vaccine under the PreHevbrio, PreHevbri, and Sci-B-Vac brand names. The company... also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma cancer vaccine immunotherapeutic candidate; VBI-1501, a prophylactic cytomegalovirus vaccine candidate; and VBI-2501 to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited, the National Research Council of Canada, and Coalition for Epidemic Preparedness Innovations. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts. Read more
President, CEO & Director
Mr. Jeffery R. Baxter FCMA
President, CEO & Director
Mr. Jeffery R. Baxter FCMA
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of VBI Vaccines Inc New (Canada) (VBIV) is $0.02 (NASDAQ) as of 06-Sep-2024 09:30 EDT. VBI Vaccines Inc New (Canada) (VBIV) has given a return of -94.41% in the last 3 years.
Since, TTM earnings of VBI Vaccines Inc New (Canada) (VBIV) is negative, P/E ratio is not available.
The P/B ratio of VBI Vaccines Inc New (Canada) (VBIV) is 1.24 times as on 06-Sep-2024, a 80 discount to its peers’ median range of 6.26 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
The 52-week high and low of VBI Vaccines Inc New (Canada) (VBIV) are Rs -- and Rs -- as of 26-Apr-2026.
VBI Vaccines Inc New (Canada) (VBIV) has a market capitalisation of $ 2 Mln as on 06-Sep-2024. As per SEBI classification, it is a Small Cap company.
Before investing in VBI Vaccines Inc New (Canada) (VBIV), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.